ORIC (ORIC) CFO exercises options and sells 52,000 shares in 10b5-1 trades

Rhea-AI Filing Summary

Oric Pharmaceuticals Chief Financial Officer Dominic Piscitelli reported option exercises and share sales in Oric Pharmaceuticals, Inc. common stock. On February 24, 2026, he exercised stock options for 52,000 shares at an exercise price of $4.36 per share, increasing his common stock holdings before any sale.

On the same date, he then sold 52,000 shares of common stock in open-market transactions at a weighted average price of $13.5132 per share, within a range of $13.50 to $13.53, under a pre-arranged Rule 10b5-1 trading plan adopted on June 24, 2025. Following these transactions, he directly owned 68,148 shares of Oric Pharmaceuticals common stock.

Insider Trade Summary

Net Seller: 52,000 shares ($702,686)

Net Sell 3 txns

Insider Piscitelli Dominic

Role Chief Financial Officer

Sold 52,000 shs ($703K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	52,000	$0.00	--
Exercise	Common Stock	52,000	$4.36	$227K
Sale	Common Stock	52,000	$13.5132	$703K

Holdings After Transaction: Stock Option (right to buy) — 144,500 shares (Direct); Common Stock — 120,148 shares (Direct)

Footnotes (1)

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025. Represents the weighted average share price of an aggregate total of 52,000 shares sold in the price range of $13.50 to $13.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Piscitelli Dominic

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		M		52,000	A	$4.36	120,148	D
Common Stock	02/24/2026		S(1)		52,000	D	$13.5132(2)	68,148	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.36	02/24/2026		M			52,000	07/20/2025	07/19/2032	Common Stock	52,000	$0	144,500	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025.

2. Represents the weighted average share price of an aggregate total of 52,000 shares sold in the price range of $13.50 to $13.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Christian Kuhlen, attorney-in-fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.